LabAnswer Selects John F. Conway as Director of R & D Strategy
News Feb 25, 2014
LabAnswer, one of the nation’s leading laboratory informatics consultancies, has announced the formation of a new position, Director of R & D Strategy and named John F. Conway to the position. John will strategize and architect scientific data management systems to streamline R&D processes for leading life science, chemical, consumer product, and process manufacturing organizations.
John comes to LabAnswer with 20 years of R&D experience. Most recently, he was with Schrödinger, LLC, where he was Vice President of Professional Services and Solutions. John’s focus was to expand Schrodinger’s footprint in scientific informatics.
Previously, John was Global Director of Scientific Informatics and Solutions at Accelrys, Inc. It was there that John helped bring both the concept of Biological Entity Registration and Next Generation LIMS to market. In addition, John and his teams were responsible for building small and large molecule design environments. Before he joined Accelrys, he was the Philadelphia Site Head, Global Chair of the Structural Biology Domain, and head of US Lab Automation for the Discovery Informatics Department at GlaxoSmithKline, Inc. Prior to GSK, John spent many years at Merck and Co., Inc. with varying roles in biological and chemical informatics as well as computational science methods and modeling.
John’s early career includes serving as an analytical biochemist at Tektagen, Inc. (now Charles River Laboratories), a Senior Forensic Scientist at the Pennsylvania State Police, and Co-Founder of Avecon, a diverse diagnostics company. His education includes biochemistry and molecular biology at Pennsylvania State University and Lehigh University.
“I could not be more pleased and excited knowing that I will be helping LabAnswer clients to rethink how to manage the R&D informatics space,” states Conway.
“We are pleased to have someone of John’s stature join our team. In his new role at LabAnswer, John and his team are solely focused on architecting the best possible systems for our clients with an unbiased approach to drive superior outcomes,” adds Mark Everding, LabAnswer President / CEO.
With machine learning systems now being used to determine everything from stock prices to medical diagnoses, it's never been more important to look at how they arrive at decisions. A new approach out of MIT demonstrates that the main culprit is not just the algorithms themselves, but how the data itself is collected.